Drug General Information
Drug ID	D03PWD
Former ID	DIB014124
Drug Name	GMI-1271
Indication	Acute myeloid leukemia [ICD9: 205; ICD10:C92.0]		Phase 1	[524962]
Company	Glycomimetics
Structure		Download 2D MOL
Target and Pathway
Target(s)	E-selectin	Target Info	Inhibitor	[550826]
KEGG Pathway	Cell adhesion molecules (CAMs)
	TNF signaling pathway
	African trypanosomiasis
	Malaria
NetPath Pathway	IL5 Signaling Pathway
	IL4 Signaling Pathway
	TNFalpha Signaling Pathway
	ID Signaling Pathway
Pathway Interaction Database	Thromboxane A2 receptor signaling
	Glucocorticoid receptor regulatory network
	ATF-2 transcription factor network
Reactome	Cell surface interactions at the vascular wall
WikiPathways	Human Complement System
	TNF alpha Signaling Pathway
	Cell surface interactions at the vascular wall
References
Ref 524962	ClinicalTrials.gov (NCT02271113) Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects. U.S. National Institutes of Health.
Ref 550826	Clinical pipeline report, company report or official report of glycomimetics.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.